A Czech biotech bets big on rising ADC player LegoChem as part of licensing pact aimed at solid tumors

Kyle Blankenship

Czech biotech Sotio will pay $29.5 million upfront and in near-term milestones with a potential $1.03 billion in downstream biobucks to license five antibody-drug conjugate …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

A Czech biotech bets big on rising ADC player LegoChem as part of licensing pact aimed at solid tumors

Kyle Blankenship

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

A Czech biotech bets big on ris­ing ADC play­er LegoChem as part of li­cens­ing pact aimed at sol­id tu­mors

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

A Czech biotech bets big on rising ADC player LegoChem as part of licensing pact aimed at solid tumors